» Articles » PMID: 24477192

Treatment of Chemotherapy-induced Neutropenia in a Rat Model by Using Multiple Daily Doses of Oral Administration of G-CSF-containing Nanoparticles

Overview
Journal Biomaterials
Date 2014 Jan 31
PMID 24477192
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy-induced neutropenia often increases the likelihood of life-threatening infections. In this study, a nanoparticle (NP) system composed of chitosan and poly(γ-glutamic acid) conjugated with diethylene triamine pentaacetic acid (γPGA-DTPA) was prepared for oral delivery of granulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor. The therapeutic potential of this NP system for daily administration of G-CSF to treat neutropenia associated with chemotherapy was evaluated in a rat model. In vitro results indicate that the procedures of NP loading and release preserved the structural integrity and bioactivity of the G-CSF molecules adequately. Those results further demonstrated the enzymatic inhibition activity of γPGA-DTPA towards G-CSF against intestinal proteases. Additionally, the in vivo biodistribution study clearly identified accumulations of G-CSF in the heart, liver, bone marrow, and urinary bladder, an indication of systemic absorption of G-CSF; its relative bioavailability was approximately 13.6%. Moreover, significant glucose uptake was observed in bone marrow during G-CSF treatment, suggesting increased bone marrow metabolism and neutrophil production. Consequently, neutrophil count in the blood increased in a sustained manner; this fact may help a patient's immune system recover from the side effects of chemotherapy.

Citing Articles

Combating bone marrow failure with polymer materials.

Koch K, Jadon N, Thesmar I, Tew G, Minter L Front Immunol. 2024; 15:1396486.

PMID: 38694497 PMC: 11061490. DOI: 10.3389/fimmu.2024.1396486.


Potential of Nuclear Imaging Techniques to Study the Oral Delivery of Peptides.

Saxena T, Sie C, Lin K, Ye D, Saatchi K, Hafeli U Pharmaceutics. 2022; 14(12).

PMID: 36559303 PMC: 9780892. DOI: 10.3390/pharmaceutics14122809.